News

Advanced Life Sciences (ADLS) has received a complete response letter from FDA, regarding its New Drug Application (NDA) for Restanza (cethromycin) for the outpatient treatment of adults with

Pharmasset has reported positive preliminary results from phase I clinical trial of PSI-7851, for the treatment of hepatitis C (HCV). PSI-7851 is a second generation nucleotide polymerase inhibitor

FDA’s Arthritis Advisory Committee has confirmed that it will review Auxilium’s Xiaflex, during an advisory committee hearing at the Holiday Inn in Gaithersburg, MD on September 16, 2009.

Inspire Pharmaceuticals has posted a net loss of $9.5m or $0.17 per share for the second quarter which ended on June 30, 2009, compared to a net loss

The Addario Lung Cancer Medical Institute (ALCMI) has signed a letter of intent (LOI) collaboration agreement with Response Genetics (RGI), on molecular diagnostic testing and banking of advanced-stage

Allergan reported $0.58 diluted earnings per share attributable to stockholders compared to $0.47 diluted earnings per share attributable to stockholders reported for the second quarter of 2008. Allergan’s

Oculus Innovative Sciences has announced the closing of an offering to sell securities to selected investors, for aggregate gross proceeds of approximately $6 million. The offering was made

FDA’s Arthritis Advisory Committee has confirmed that it will review Auxilium’s Xiaflex during an advisory committee hearing at the Holiday Inn in Gaithersburg, MD, on September 16, 2009.

Antigenics has entered into definitive agreements to sell in a private placement of approximately 5 million shares of its common stock at a price of $2.00 per share.